Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

Anna Énzsöly, Katalin Markó, T. Tábi, É. Szökő, R. Zelkó, Miklós Tóth, J. Mark Petrash, P. Mátyus, J. Németh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization.

Original languageEnglish
Pages (from-to)969-975
Number of pages7
JournalJournal of Neural Transmission
Volume120
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Corneal Neovascularization
Amine Oxidase (Copper-Containing)
Adhesives
Blood Vessels
Rabbits
Proteins
Angiogenesis Inhibitors
Cornea
Sutures
Anti-Inflammatory Agents
Observation
N'-(2-phenylallyl)hydrazine

Keywords

  • Cornea
  • LJP 1207
  • Neovascularization
  • VAP-1/SSAO

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model. / Énzsöly, Anna; Markó, Katalin; Tábi, T.; Szökő, É.; Zelkó, R.; Tóth, Miklós; Mark Petrash, J.; Mátyus, P.; Németh, J.

In: Journal of Neural Transmission, Vol. 120, No. 6, 06.2013, p. 969-975.

Research output: Contribution to journalArticle

@article{45c667ff46c24a648eaa27f877e99fb7,
title = "Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model",
abstract = "The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization.",
keywords = "Cornea, LJP 1207, Neovascularization, VAP-1/SSAO",
author = "Anna {\'E}nzs{\"o}ly and Katalin Mark{\'o} and T. T{\'a}bi and {\'E}. Sz{\"o}kő and R. Zelk{\'o} and Mikl{\'o}s T{\'o}th and {Mark Petrash}, J. and P. M{\'a}tyus and J. N{\'e}meth",
year = "2013",
month = "6",
doi = "10.1007/s00702-013-0986-0",
language = "English",
volume = "120",
pages = "969--975",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

AU - Énzsöly, Anna

AU - Markó, Katalin

AU - Tábi, T.

AU - Szökő, É.

AU - Zelkó, R.

AU - Tóth, Miklós

AU - Mark Petrash, J.

AU - Mátyus, P.

AU - Németh, J.

PY - 2013/6

Y1 - 2013/6

N2 - The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization.

AB - The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization.

KW - Cornea

KW - LJP 1207

KW - Neovascularization

KW - VAP-1/SSAO

UR - http://www.scopus.com/inward/record.url?scp=84878702712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878702712&partnerID=8YFLogxK

U2 - 10.1007/s00702-013-0986-0

DO - 10.1007/s00702-013-0986-0

M3 - Article

C2 - 23397320

AN - SCOPUS:84878702712

VL - 120

SP - 969

EP - 975

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 6

ER -